Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myer
A phase 3 trial of MSD’s anti-TIGIT antibody vibostolimab and PD-1 inhibitor pembrolizumab has been abandoned after a high rate of discontinuations rendered the study futi
Monitoring of heart failure patients in their homes using a wearable developed by Analog Devices Inc (ADI) has shown in a new study that it may be able to reduce costly ho
After patients enrol in clinical trials, regular assessments and testing – often requiring clinic visits – can become onerous and reduce the chances they will stick with t
The death of a young boy with Duchenne muscular dystrophy (DMD) who was treated with Pfizer’s experimental gene therapy in a phase 2 trial has prompted the company to paus